Enanta Pharmaceuticals, Inc. (ENTA) Stock Price & Analysis

Enanta Pharmaceuticals, Inc. (ENTA) is trading at USD 8.14, down 6.35% today, as of November 18, 2026 at 20:43 UTC (US market open; quotes may be delayed), according to Nexqual market data.

ENTA last closed at USD 8.14; today's session has ranged USD 8.11–8.75 on volume of 628,251 shares. Market capitalization is —, with a 52-week range of USD 8.11–17.15 (NMS). Source: Nexqual, retrieved November 18, 2026 at 20:43 UTC.

Also available as compact Markdown for AI agents: nexqual.com/ENTA.md

Latest Earnings Results (ENTA)

Enanta Pharmaceuticals, Inc. (ENTA) reported Q4 2026 results on Nov 16, 2026, 4:10:15 PM ET: GAAP EPS -$0.81 vs. estimate -$0.77 (miss), revenue $12.87M vs. estimate $15.72M (miss). Guidance: The company expects its current cash, cash equivalents and marketable securities, as well as its retained portion of future royalty revenue, will be sufficient to meet the anticipated cash requirements of its existing business and development programs into fiscal 2029. Source: SEC 8-K filing. Nexqual published it 17 min 49 s after release. Read the SEC filing. Full report with estimates: nexqual.com/earnings/2026-11-16/ENTA.

Fiscal periodEPS (reported)RevenueReleasedSource
Q4 2026-$0.81 (GAAP diluted)$12.9MNov 16, 2026, 4:10:15 PM ET · on Nexqual +17 min 49 sSEC 8-K filing

Reported actuals captured by Nexqual from SEC 8-K filings and company press releases; each figure confirmed by two independent extraction methods.

Key facts (ENTA)

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ENTA)

USDFY2021FY2022FY2023FY2024FY2025TTM
Revenue$97.1M$86.2M$79.2M$67.6M$65.3M$65.3M
Operating income-$110M-$124M-$137M-$122M-$85.3M-$58.7M
Net income-$79.0M-$122M-$134M-$116M-$81.9M-$63.2M
EPS (diluted)-$3.92-$5.91-$6.38-$5.48-$3.84—
Free cash flow-$70.7M-$86.9M-$112M-$96.7M-$32.2M-$36.9M
Operating margin-112.9%-143.7%-173.2%-179.9%-130.7%-90.0%
Net margin-81.4%-141.3%-169.0%-171.6%-125.4%-96.9%
Revenue growth-20.7%-11.2%-8.1%-14.6%-3.4%—
Cash + short-term investments$244M$249M$370M$248M$189M—

Fiscal years end Sep. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (ENTA)

Analysts (ENTA)

Rating changes, last 120 days:

DateFirmActionRatingPrice target
2026-09-23HC Wainwright & Co.ReiteratedBuy$20

Total return (dividends reinvested) (ENTA)

1Y (from 2025-11-18)5Y (from 2021-11-15)
Total return-34.1%-89.2%
S&P 500 (SPY)+11.9%+66.7%
Per year-34.2%-35.9%
Volatility (annualized)53.5%66.3%
Max drawdown-51.7% (Dec 2025→Nov 2026)-94.9% (Nov 2021→Apr 2025)

Dividends (ENTA)

ENTA paid no cash dividend in the last five years.

Short interest (ENTA)

1,856,510 shares sold short, 7.63% of the float, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 2,552,994 shares (-27.3%). Days to cover: 7.0 (short shares ÷ average daily volume).

ENTA earnings history and stock reaction

Results filedQuarterEPSConsensusSurpriseStock reaction
Nov 16, 2026Quarter ended Sep 30, 2026−$0.81−$0.77Miss −5.2%-20.9%
Aug 10, 2026Quarter ended Jun 30, 2026−$0.67−$0.53Miss −26.4%-1.8%
May 11, 2026Quarter ended Mar 31, 2026−$0.45−$0.57Beat +21.1%-5.3%
Feb 9, 2026Quarter ended Dec 31, 2025−$0.42−$0.80Beat +47.5%+4.6%
Nov 17, 2025————+2.5%
Aug 11, 2025————-0.6%
May 12, 2025————-0.8%
Feb 10, 2025————+14.1%

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

ENTA recent SEC filings (last 120 days)

FiledFormWhat it says
Nov 18, 202610-KAnnual report · period ended Sep 30, 2026
Nov 16, 2026Schedule 13GADAR1 Capital Management, LLC, Daniel Schneeberger: 6.0% of shares, passive 5%+ holder
Nov 16, 20268-KQuarterly results
Nov 16, 2026Schedule 13G/AFarallon Capital Management, L.L.C., Dapice Joshua J.: 3.3% of shares, passive 5%+ holder (amended)
Oct 29, 20268-KOther material event
“As previously disclosed, Enanta Pharmaceuticals, Inc. (the "Company") filed a patent infringement action in the Unified Patent Court (the "UPC") of the European Union against Pfizer Inc. and certain of its subsidiaries, seeking a determination of liability for infringement of European Patent No. EP 4 051 265 (the " 265 Patent") in connection with Pfizer's manufacture, use, and sale of Paxlovid (nirmatrelvir tablets; ritonavir tablets) in the 18 EU member states participating in the UPC. Pfizer counterclaimed for…”
Oct 28, 20268-KDirector or executive officer change, or pay arrangement; Regulation FD disclosure
“On October 28, 2026, Enanta Pharmaceuticals, Inc. (the "Company") and Jay R. Luly, Ph.D., age 70, announced Dr. Luly's intention to retire as President and Chief Executive Officer by February 1, 2027, following 23 years of leadership with the Company. The Company expects to enter into an agreement with Dr. Luly for his continued service as a strategic advisor for the remainder of 2027. The Board of Directors (the "Board") of the Company has initiated a comprehensive search for Dr. Luly's successor, considering…”
Oct 27, 2026Schedule 13GBlackRock Portfolio Management LLC: 5.4% of shares, passive 5%+ holder
Aug 14, 2026Schedule 13G/ADeep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd.: 5.0% of shares, passive 5%+ holder (amended)
Aug 14, 2026Schedule 13G/AFarallon Capital Management, L.L.C., Farallon Capital Partners, L.P.: 8.3% of shares, passive 5%+ holder (amended)
Aug 12, 202610-QQuarterly report · period ended Jun 30, 2026
Aug 10, 20268-KQuarterly results

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

ENTA suppliers, customers and competitors (named in its 10-K)

RelationshipCompanySentence in the filing
PartnerAbbVie (ABBV)“We discovered glecaprevir, the second of two antiviral protease inhibitors developed through our collaboration with AbbVie for the treatment of acute or chronic infection with hepatitis C virus, or HCV.”
CompetitorMerck (MRK)“AbbVie's MAVYRET/MAVIRET regimen currently competes in various geographic markets and HCV patient populations with Gilead's Epclusa® (a fixed dose combination of sofosbuvir and velpatasvir), Vosevi® (a fixed-dose combination of sofosbuvir, velpatasvir and voxilaprevir approved by the FDA for certain adults previously treated with direct-acting antivirals), Harvoni® (a fixed-dose combination of sofosbuvir and ledip…”

Quoted from the company's 10-K filed Nov 18, 2026.

ENTA company outlook (results filed Nov 16, 2026)

Quoted word-for-word from the SEC 8-K results press release.

ENTA analyst estimates and revisions

PeriodEPS estimate90 days agoChangeRevenue estimateAnalysts
Current quarter (ends Dec 2026)$-0.33$-0.41+$0.08$14.3M1
Next quarter (ends Mar 2027)$-0.42$-0.47+$0.05$12.5M1
Current fiscal year (ends Sep 2027)$-3.19$-2.37−$0.82$64.1M2
Next fiscal year (ends Sep 2028)$-2.27$-1.91−$0.36$86.4M4

ENTA options: expected move

Options price a move of about ±57.5% (±$5.17) by Apr 16, 2027, which includes earnings on Feb 8, 2027. Over the last 8 reports the stock moved ±6.3% on average.

ExpirationDaysATM implied volatilityExpected move
Nov 20, 20262235.1%±27.3%
Jan 15, 202758121.6%±18.4%
Apr 16, 202714996.7%±57.5%

30-day implied volatility 87% vs 81.8% realized over the last 30 trading days. Put/call ratio (volume) 34. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of November 18, 2026 at 20:43 UTC)

PriceUSD 8.14
Change▼ 6.35% (down)
Previous CloseUSD 8.14
OpenUSD 8.14
Day RangeUSD 8.11 – 8.75
52-Week RangeUSD 8.11 – 17.15
Volume628,251 shares
Market Cap—
ExchangeNMS

Technical Analysis (ENTA)

Nexqual's technical model rates ENTA "SELL" based on 3 bullish and 5 bearish signals across 129 daily candles, as of November 18, 2026 at 20:43 UTC.

Overall SignalSELL
RSI (14)26.24 (oversold)
vs SMA50Below (USD 11.68)
MACD-0.61 (negative)

Earnings (ENTA)

Next Earnings Date2027-02-08
EPS EstimateUSD -0.33
Revenue Estimate$14.32M

Recent Earnings History

QuarterActual vs Estimate
2026-09-30USD -0.81 vs est -0.77 ▼ miss
2026-06-30USD -0.67 vs est -0.54 ▼ miss
2026-03-31USD -0.45 vs est -0.57 ▲ beat
2025-12-31USD -0.42 vs est -0.8 ▲ beat

Source: Nexqual, November 18, 2026 at 20:43 UTC.

Financials & Fundamentals (ENTA)

Total Revenue$63.00M
Revenue Growth (latest quarter, YoY)-14.90%
Gross Margin+100.00%
Operating Margin-99.01%
Profit Margin-108.33%
ROE-94.19%
Debt / Equity2.22
Current Ratio3.78
Total Cash$194.51M
Total Debt$177.65M
Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K)-$36.94M (-56.6% of revenue)

Source: Nexqual, November 18, 2026 at 20:43 UTC.

Financial Health Score (ENTA)

Nexqual rates Enanta Pharmaceuticals, Inc.'s overall financial health "Weak" across five dimensions, as of November 18, 2026 at 20:43 UTC.

GrowthMixed — Revenue +0.7% (last 4 quarters to Jun 2026 vs the 4 before, SEC), slow
ProfitabilityWeak — Operating margin -90%
Balance SheetWeak — $195M cash vs $178M debt, net cash position
Cash FlowWeak — FCF negative: -$37M (last 4 quarters to Jun 2026, SEC), burning cash
EfficiencyCritical — ROE -63%, ROA -21.3% (last 4 quarters, SEC)

Ownership (ENTA)

Insider Ownership+4.67%
Institutional Ownership+91.49%
Shares Outstanding29.13M
Float22.52M
Short % of Float+7.63%

Source: Nexqual, November 18, 2026 at 20:43 UTC.

From Enanta Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2025-11-19)

Key Strengths & Strategy (as disclosed to the SEC)

Partnerships

Legal & Regulatory Risks (Item 1A, quoted)

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

SymbolNamePriceChange
KODKodiak Sciences IncUSD 98.14▲ 1.38%
BLTEBelite Bio, IncUSD 157.14▼ 0.37%
ORKAOruka Therapeutics, Inc.USD 95.92▼ 0.42%
IBRXImmunityBio, Inc.USD 6.71▲ 7.19%
IMVTImmunovant, Inc.USD 33.3▲ 0.27%
CGONCG Oncology, Inc.USD 79.9▲ 1.22%

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: November 18, 2026 at 20:43 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt